. Since the first diagnosis of NAFLD in the 1980s 1 , the incidence of the disease has reached 30% in the United States 8 , paralleling increases in the prevalence of obesity 9 (35% of adults in the United States have a BMI >30 kg/m 2 ), and in the risk of HCC 6 and cardiovascular disease in the general population 10, 11 . Although NAFLD is most commonly triggered by overnutrition coupled with a lack of exercise, environmental factors might also contribute to the rapid rise in the prevalence of both obesity and NAFLD. Indeed, diets rich in fructose have now been implicated in the development of NAFLD 1 . One class of environmental risk factors that might promote NAFLD comprises chemicals that can disrupt or alter the function of endocrine and metabolic organs such as the liver, which is the central organ controlling lipid homeostasis. These chemicals are termed endocrinedisrupting chemicals (EDCs) 12, 13 or, more recently, metabolism-disrupting chemicals 12 . The timely interest in these compounds as potential stimulators of obesity and NAFLD, along with other risk factors such as a HFD and fructose, stems from the following: many EDCs have been mass produced throughout the past four decades, driven by their widespread use (for example, bisphenol A (BPA) and phthalates in the production of plastics) 12, 13 ; animal 'intervention' studies have suggested that EDCs might cause increased adiposity or NAFLD in exposed animals 12, 13 ; and the direct measurement of EDC levels in human blood and urine has shown near-ubiquitous exposure to EDCs (for example, ≥95% of people in the United States have detectable levels of BPA in their urine 14 ). In this Review, we highlight the literature that bridges the two 'hot' topics of NAFLD and EDCs, and posit that early-life exposure to EDCs might represent an unappreciated driver of NAFLD development and progression in adulthood. We describe basic liver physiology, along with the molecular pathways that affect hepatic lipid homeostasis and how they affect NAFLD development. We then discuss various classes of EDCs that perturb 1 hepatic lipid levels; bind to nuclear hormone receptors (NRs) and recruit transcriptional co-regulators to alter the expression of genes involved in lipid homeostasis and/or to activate kinase signalling pathways; promote NAFLD in rodent models and are associated with human NAFLD; influence epigenetic modifications (that is, DNA methylation and histone modifications); and, in the setting of early-life exposures, increase susceptibility to obesity and NAFLD in adulthood.
Liver physiology
The liver is the largest glandular organ in the body. To perform its many and diverse functions, the liver relies on a compartmentalized structure. The architecture of the liver comprises small hexagonal lobules, and each lobule is connected by a network of sinusoids formed by specialized sinusoidal endothelial cells (FIG. 1) . Adjacent to the sinusoids reside hepatic stellate cells that function as a repository for lipids and vitamin A. The sinusoids traverse a collection of two other primary cell types: hepatocytes, which represent the parenchymal cell type of the liver, and Kupffer cells, which represent the resident macrophage population 15 .
Liver response to environmental cues
Although the many different cell types in the liver demonstrate considerable phenotypic and functional heterogeneity, their cooperative molecular contributions endow the liver with the ability to interpret and respond to a number of environmental stimuli. In some situations, these environmental responses have a beneficial effect on liver function and overall health. For example, in the setting of a starvation environment in utero, the liver develops in such a way that the physiological 'set points' for several liver functions, including gluco neogenesis, are primed for an adult environment in which nutrients are in short supply. In this context, the modulation of fetal development can confer a survival advantage on offspring exposed to an environment in which resources are likely to be limited, resulting in a thrifty phenotype 16 . However, individuals programmed in utero to have a thrifty pheno type (for example, as a result of famine or placental insufficiency) who go on to develop in a nutrient-rich environment instead of the 'anticipated' nutrient-poor environment are more prone to metabolic disorders. For example, prenatal exposure to famine (particularly in late gestation) during the Dutch Hunger Winter (1944) (1945) was associated with decreased glucose tolerance in adults 17 . In the same cohort, prenatal exposure to famine was associated with a more atherogenic lipid profile than was present in individuals who were not exposed to famine in utero 18 . Early-life exposure to famine during the Great Chinese Famine (1958) (1959) (1960) (1961) was associated with a sex-specific increase in the prevalence of moderate-to-severe NAFLD in adulthood, which provides direct evidence of the link between poor fetal nutrition and perturbed liver function 19 .
The basis of NAFLD
As the epicentre of metabolic homeostasis, the liver performs many functions, including haematopoiesis and the turnover of red blood cells 20 ; the production of enzymes for blood clotting; hormone biosynthesis and turnover; protein and bile synthesis; drug metabolism; lipid metabolism; glycogen storage and release; and gluconeogenesis 21 . Should any of these key functions become compromised (particularly lipid metabolism), several disease sequelae can result. An initial excess of lipid accumulation in the liver (steatosis; a reversible step) can progress to NASH (which is characterized by macrophage infiltration and inflammation), and then to fibrosis and/or cirrhosis (an irreversible step); a subset of the latter cases advance to HCC. Together, both the 'early' presenting conditions of hepatic steatosis and NASH constitute NAFLD 5, 10 (FIG. 1) .
NAFLD is an increasing problem in HFD-consuming countries such as the United States. For example, an analysis of steatosis (as assayed by ultrasound) in viral hepatitis-negative patients in the US National Health and Nutrition Examination Survey (NHANES) has suggested that the prevalence of NAFLD increased from 18% in 1998-1991 to 31% in 2011-2012 (REF. 8 ). At 31%, this prevalence corresponds to ~75-100 million people in the United States 11 . The large increase in NAFLD incidence throughout the past two decades has been accompanied by an increased risk of HCC among patients with NAFLD 6 and an increased number of resultant deaths, as well as an increased risk of cardiovascular disease among these patients 10, 11 . Importantly, NASH -the inflammatory form of NAFLD -is currently the second leading cause of liver disease in adults scheduled for liver transplantation in the United States 10 . Thus, understanding the factors that trigger NAFLD is of the utmost importance in curbing the rising need for liver transplantation and in preventing the occurrence of later-stage lethal events such as HCC. Among the environmental factors that contribute to the development of NAFLD, early-life exposure to EDCs might represent an unappreciated risk factor to consider in addition to obesity and type 2 diabetes mellitus (T2DM) 22 , owing to their potential to alter lipid homeostatic set points and thus promote NAFLD.
Hepatic lipid homeostasis is maintained by the hepatocyte uptake and de novo synthesis of free fatty acids (FFAs), FFA disposal by oxidation or de novo triglyceride synthesis, and by the export of triglycerides from hepatocytes as VLDL (FIG. 2) . Steatosis develops when the (FIG. 2) . Although triglycerides are not inherently hepatotoxic, aberrant hepatocyte processing of FFAs activates resident and infiltrating macrophages through Toll-like receptor 4-induced signalling pathways to initiate a pro-inflammatory cascade that contributes to NAFLD 3, 24 . The chemokine and angiogenic signals produced by infiltrating macrophages lead to the dysregulation of the sinusoidal endothelial cells that form the fenestrated vasculature of the liver 25 . An excess of hepatic lipids also serves as an activation signal for the normally quiescent stellate cells and thus initiates the fibrotic process that often accompanies more severe forms of liver disease such as NASH and HCC 3, 4, 23 (FIG. 1) .
Environmental exposures. Established risk factors for NAFLD in humans include obesity and insulin resistance or T2DM 22, 26, 27 , as well as specific genetic mutations that result in increased lipid synthesis and uptake, and/or decreased FFA oxidation and triglyceride export 28 . However, such germline mutations are rare and would not explain the vast majority of NAFLD cases, which points to the involvement of environmental factors in the development of this disease. For example, dietary intake of saturated fat, trans-fatty acids, carbohydrate and simple sugars (fructose and sucrose) might contribute to aberrant hepatic lipid accumulation 26 . Interestingly, some polyunsaturated fatty acids (PUFAs), such as n-3 PUFAs like α-linolenic acid, seem to reduce an individual's risk of developing NAFLD 3 . However, whether true causal relationships between these nutrients and NAFLD exist remains to be fully determined. Of these dietary factors, fructose has been reported to be a risk factor for human NAFLD 1, 3, [29] [30] [31] , but whether fructose alone (for example, in the absence of obesity) can trigger or facilitate the progression of NAFLD is still debatable 26 . Finally, maternal diet might affect the susceptibility of offspring to NAFLD via changes in the neonatal or infant-gut microbiota, although again, causality remains to be firmly established 2 
.
Of the various environmental chemical exposures that might negatively affect the liver, the growing class of EDCs has gained attention owing to their ability to perturb hepatic function. EDCs are defined as compounds that exert adverse health effects secondary to the disruption of the endocrine system. Structurally, EDCs comprise a wide range of both natural and man-made substances that are derived from persistent organic pollutants (POPs; that is, dioxins, benzo[a]pyrene and polychlorinated biphenyls (PCBs)), organochlorines (such as dichlorodiphenyltrichloroethane (DDT) and its metabolite dichlorodiphenyldichloroethylene (DDE)), plasticizers (such as BPA), phthalates (such as di-2-ethylhexyl phthalate (DEHP)), organotins (such as tributyltin (TBT)), polyfluoroalkyls (such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS)) and other pesticides (such as cypermethrin (CYP), atrazine (ATZ) and carbendazim) 13, 32 . Accumulating evidence suggests that these EDCs -many of which are also sequestered and metabolized in the liver -might contribute to the development of NAFLD.
Relevant to the NAFLD-obesity link, several of these EDCs -including BPA, TBT, PCBs, phthalates, PFOA and PFOS -are classified as 'obesogens' on the basis of animal studies showing that early-life exposure to these EDCs promotes obesity later in adulthood 33 .The original obesogen hypothesis proposed by Grun and Blumberg 34 primarily focused on the effects of these EDCs on adipocytes (that is, fat storage) and pancreatic β cells (that is, insulin secretion) 34, 35 . In rodent models, perinatal exposure to obesogens increases fat mass in both male and 32, 34, 36 . Thus, one pathway by which EDCs might influence the development of NAFLD is through the peripheral effects of obesity on adipose dysfunction and the deregulation of the satiety axis in the hypothalamus, as well as liver cell-autonomous effects.
Liver fat metabolism and EDCs

Nuclear receptors and co-regulators
The vast majority of EDCs exert their activity as endocrine disruptors via their ability to bind to NRs, and thus act as NR agonists or antagonists. The liver expresses an extensive repertoire of NRs that have important roles in hepatic lipid metabolism (FIG. 3) . When activated by a ligand, the classical activity of NRs involves docking at response elements in the promoter or enhancer regions of target genes, followed by the binding of steroid receptor co-activator (SRC) complexes that recruit additional co-regulators that have histone-modifying enzymatic activities, such as acetylases and methylases 37, 38 . The concerted action of these co-regulators leads to the trans activation of target gene programmes 37 . Experience with selective oestrogen receptor modulators (SERMs) 39 as well as EDCs 40 has shown that for agonists, NRs adopt an active conformation and interact with co-activators, whereas for antagonists, receptors adopt an inactive conformation that recruits co-repressors. In addition to classical genomic activity, ligand-dependent NR signalling also occurs in the cytoplasm and is referred to as 'non-genomic' signalling 41, 42 . This extranuclear NR signalling results in the activation of kinases -such as AKT (also known as protein kinase B) and mitogenactivated protein kinases (MAPKs) -and downstream signalling pathways that mediate biological responses independently of NR nuclear localization. Non-genomic signalling is characterized by its rapid action, and occurs independently of RNA or protein synthesis.
Several NRs have roles in non-genomic signalling. Perhaps the most prominent of these are the steroid hormone receptors oestrogen receptor-α (ERα), ERβ, androgen receptor (AR) and progesterone receptor (PR) 43, 44 . In addition to these steroid hormone receptors, accumulating evidence suggests that other NRs (for example, peroxisome proliferator-activated receptor-γ (PPARγ) 45 , retinoid X receptor-α (RXRα) 46 , truncated thyroid hormone receptor-α (TRα) isoforms 44, 47 and retinoic acid receptors (RARα and RARγ 48 )) might also signal via a similar mechanism. Non-genomic signalling does have the potential to affect the genome and alter transcription, as kinases activated in non-genomic signalling pathways can phosphorylate and regulate the activity of epigenomic programmers, transcription factors and/or their associated co-regulators, even in the absence of an interaction between a liganded NR and its target genes.
Transcriptional profiling of all major isoforms of the 49 known NRs from isolated livers of 129/SvJ and C57BL/6J male mice revealed hepatic expression of 39 NRs
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. A similar number of NRs (35) were identified by mass spectrometric profiling of NRs bound to their cognate DNA response elements in hepatocytes isolated from male and female C57BL/6J mice 50 . Of these, the NR1 subfamily receptors that heterodimerize with RXRs (RXRα, RXRβ and RXRγ) -which includes PPARα, PPARβ, PPARγ, the liver X receptors (LXRα and LXRβ), farnesoid X receptor-α (FXRα), constitutive androstane receptor (CAR; also known as NR1I3), pregnane X receptor (PXR) and TRs -have been implicated in the modulation of NAFLD development [51] [52] [53] (FIG. 3) . The activation of PPARα by its natural ligands (FFAs) increases the expression of genes that encode enzymes involved in FFA oxidation (such as CPT1A (which encodes carnitine O-palmitoyltransferase 1 liver isoform) and ACOX1 (which encodes peroxisomal acyl-coenzyme A oxidase 1)) and hence leads to decreased hepatic steatosis 54 . Similarly, xenobiotics bind to and activate CAR and PXR; however, species-specific differences clearly exist 55, 56 . For example, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene activates the mouse but not the human CAR 57, 58 , whereas 6-( (3,4-dichlorobenzyl) oxime activates the human but not the mouse CAR 55, 56, 59 . In addition, pregnenolone 16α-carbonitrile preferentially activates the mouse and rat PXRs rather than the human PXR 57,60-63 , but rifampicin and SR12813 are specific Mechanistically, the uptake of dietary fats is facilitated by the release of bile acids that are synthesized in the liver and secreted by the gall bladder into the intestine. Bile salts emulsify fat, creating free fatty acids (FFAs) and monoglycerides, which are rapidly absorbed by enterocytes of the intestine. In the intestine, FFAs and monoglycerides are resynthesized into triglycerides, which are packaged into chylomicrons and taken up by the liver via receptor-mediated endocytosis. The liver is also responsible for converting carbohydrates and protein into FFAs, which are packaged into triglycerides and exported from the liver as VLDL. The liver is also the primary source of the β-oxidation that serves to metabolize FFAs to produce energy in the form of ATP, as well as to generate ketone bodies that are used as an alternative fuel source during periods of fasting. Altogether, the balance between lipid uptake and release, and triglyceride synthesis and β-oxidation, helps to preserve energy homeostasis in the liver. The disruption of these processes by a high-fat diet (HFD) is accompanied by aberrant lipid accumulation in the liver, which leads to a cascade of pathologies that range from steatosis to hepatocellular carcinoma. Endocrine-disrupting chemicals can also promote nonalcoholic fatty liver disease (NAFLD) -either alone or in combination with a HFDby increasing FFA uptake, increasing de novo lipogenesis, decreasing triglyceride export as VLDL and/or decreasing FFA β-oxidation. 64, 65 . LXRs bind to oxysterols and activate gene programmes that express proteins involved in lipogenesis (for example, FAS and sterol regulatory element-binding transcription factor 1 (SREBP1)), which can lead to lipid accumulation in the liver 66 . FXRα functionally responds to bile acids, and induces the expression of genes that encode bile acid exporters and NR0B2, which encodes nuclear receptor subfamily 0 group B member 2 (also known as short heterodimer partner (SHP)), a receptor that represses SREBP1 expression 67 , thereby decreasing hepatic steatosis. Owing to this action, FXRα agonists such as obeticholic acid and INT-767 are currently being tested for reduction of NAFLD and NASH in clinical trials 2 . Thyroid hormone T 3 , as well as synthetic TR agonists, reduce hepatic steatosis in male Fischer 344 rats fed a diet deficient in choline and methionine 68 and in diabetic mice (for example, ob/ob mice) 69 , which is suggestive of their potential clinical usefulness. The activation of a NR that can promote steatosis does not always result in increased inflammation. For example, the activation of PXR induces the expression of genes involved in lipogenesis (for example, SCD1; which encodes stearoylCoA desaturase) and suppresses the expression of genes that encode enzymes involved in FFA oxidation (for example, CPT1A) 70 , yet PXR activation can also suppress the expression of inflammatory cytokines in hepatocytes treated with lipopolysaccharide 71 . In addition to NRs that bind to EDCs, co-regulators that complex with liganded NRs might also have a role in NAFLD. The activity of NRs bound to endogenous ligands or EDCs is determined by the action of co-regulator proteins that interact with these receptors. In the liver, a variety of co-regulators have key functional roles in hepatic lipid metabolism as they are recruited to ligand-activated NRs bound at genes involved in lipid homeostasis (FIG. 4) . Examples of crucial co-activators are the three SRC family proteins (SRC1, SRC2 and SRC3; also known as NCOA1, NCOA2 and NCOA3, respectively), PPARγ co-activators (PGC1α and PGC1β) and mediator of RNA polymerase II transcription subunit 1 (MED1). The key co-repressors are the nuclear receptor co-repressor (NCOR) or silencing mediator of retinoic acid and thyroid hormone receptor (SMRT; also known as NCOR2) complexes, which contain histone deacetylase 3 (HDAC3), and receptor-interacting protein 140 (RIP140; also known as NR-interacting protein 1) 72 . Studies in knockout mice clearly show that NR coactivators have an important role in the development of steatosis. Ablation of Src1 increased acylcarnitine levels in the fed-to-fasting transition, which is suggestive of an important role for SRC1 in regulating hepatic FFA oxidation 73 . Both whole-body and liver-specific ablation of Src2 phenocopy a Von Gierke-like disease that is characterized by fasting hypoglycaemia, hepatic steatosis, and increased circulating levels of triglycerides, cholesterol and FFAs
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. Hepatic mRNA and protein levels of SRC3 increase upon HFD feeding, and ablation of Src3 protects against HFD-induced hepatic steatosis by reducing lipid accumulation and the accompanying inflammatory response [75] [76] [77] . Whole-body ablation of Pgc1a and Pgc1b (which encode PGC1α and PGC1β, respectively) results in increased hepatic steatosis, although liver-specific deletion is needed to confirm whether these effects are [78] [79] [80] . Interestingly, PGC1α mediates the recruitment of the BRG1-associated factor 60A (BAF60A; also known as SMARCD1) subunit of the SWI/SNF chromatin-remodelling complex to PPARα-binding sites, which leads to the transcriptional activation of genes involved in FFA oxidation; mice that overexpress BAF60A and are fed a HFD display ameliorated steatosis 81 . Finally, MED1 is the key subunit of the Mediator complex that interacts with liganded NRs via its LxxLL motifs 82 . MED1 is required for HFD-induced hepatic stea tosis as well as PPARγ-stimulated hepatic steatosis, as revealed by the analysis of liver-specific Med1-knockout mice and hepatic Pparg overexpression achieved by tail vein adenovirus injection 83 . Studies in knockout mice also highlight the importance of specific NR co-repressors in modulating hepatic steatosis. For example, NCOR and SMRT each associate with HDAC3 as part of a multisubunit protein complex that generally functions as a NR co-repressor [84] [85] [86] . Liver-specific ablation of Hdac3 or Ncor, but not Smrt, in mice results in hepatic steatosis 87, 88 . Whole-body Rip140-knockout mice are lean and resistant to HFDinduced obesity and hepatic steatosis 89 . Liver-specific deletion of Rip140 also reduces hepatic lipid levels in mice, which suggests that RIP140 serves as a co-repressor of LXR-activated genes that are involved in lipogenesis, such as Fas and Srebp1 (REF. 90 ). Other studies have identified additional NR co-repressors that regulate hepatic steatosis, such as ligand-dependent co-repressor (LCOR), which suppresses the TRβ-induced expression of genes involved in lipogenesis and ameliorates hepatic steatosis in obese mice 91 , and small heterodimer partner-interacting leucine zipper protein (SMILE; also known as TMTC3), which represses LXRα-mediated Srebp1 expression and hepatic lipid accumulation 92 . Although the above-mentioned animal gene-ablation studies emphasize the importance of co-regulators in modulating hepatic lipid homeostasis, information on which cell types in the liver are critical to the development of steatosis is lacking, emphasizing the need for liver cell type-specific genetic ablation studies.
Like endogenous hormones, EDCs can activate both the genomic and non-genomic actions of NRs, and induce post-translational modifications that modulate NR and/or co-regulator activity. For example, SRC3 is initially phosphorylated on a subset of conserved phosphorylation sites by oestradiol-activated kinases in the cytoplasm, and this subsequently leads to increased NR-SRC3 target gene transcription 93, 94 . Mice harbouring loss-of-function mutations in four of these conserved phosphorylation sites in SRC3 develop insulin resistance, dyslipidaemia, liver steatosis and accelerated hepatic tumorigenesis 95 . Furthermore, insulin (a mimic of the fed state) activates AKT, resulting in the phosphorylation of NCOR on Ser1460, which promotes its interaction with PPARα rather than LXRα, and results in the repression of PPARα activity, decreased FFA oxidation and increased hepatic lipogenesis 96 (FIG. 4) .
Different structural classes of EDCs have been shown to modulate the activity of NRs expressed in the liver and to be associated with NAFLD 32, 97, 98 (FIG. 3) . POPs -such as dioxins, benzo[a]pyrene and some PCBsbind to and activate AHR (some also bind to PPARγ and ERs); organochlorines such as DDT bind to and activate CAR and ERα; the plasticizer BPA binds to and activates ERs and GR, yet represses TRs; organotins such as TBT bind to and activate RXRs and PPARγ; polyfluoroalkyls such as PFOA and PFOS bind to and activate ERs and PPARs; and phthalates such as DEHP bind to and activate PPARs, CAR, PXR and GR 32 . Some of the EDC-NR interactions are of low affinity (for example, the equilibrium dissociation constant ( The EDC-NAFLD link EDC-induced activation of NRs has been proposed to be an initiating event in the development of steatosis 101 , as well as to promote the transition of steatosis to steatohepatitis 102 . Several EDCs that function as ligands for the NRs described above have been shown to affect the liver and the development of NAFLD 12, 101, 102 . A 2015 review of 371 studies in federal databases suggested that 123 unique environmental chemicals are associated with NAFLD in rodents, with pesticides representing the majority (44%), and PCBs and dioxins being the most potent on Figure 4 | The potential genomic mechanism of action of endocrine-disrupting chemicals. Once an endocrine-disrupting chemical (EDC) enters the liver, it is bound by specific nuclear hormone receptors (NRs). This action can either positively or negatively affect the transcription of genes involved in lipid homeostasis via specific EDC-NR complexes that recruit co-activators or co-repressors to target genes. Key co-activators that modulate steatosis progression include steroid receptor co-activators (SRCs), peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α) and mediator of RNA polymerase II transcription subunit 1 (MED1), whereas nuclear receptor co-repressor (NCOR) or silencing mediator of retinoic acid and thyroid hormone receptor (SMRT; also known as NCOR2) complexes, which contain histone deacetylase 3 (HDAC3), receptor-interacting protein 140 (RIP140) and ligand-dependent co-repressor (LCOR) act as co-repressors. Co-activator complexes induce histone modifications that are associated with active gene transcription, such as acetylation (Ac) and methylation (Me), whereas co-repressors generally recruit associated histone deacetylases or demethylases to remove these marks. SRCs and NCOR are subject to regulatory phosphorylation (P) events. The engagement of co-regulators by EDC-bound NRs results in the modulation of gene cassettes that encode proteins involved in lipid homeostasis and/or the reprogramming of the epigenome, which ultimately promotes nonalcoholic fatty liver disease (NAFLD) via, for example, increased lipogenesis gene expression and/or inhibiting the expression of genes involved in free fatty acid oxidation. the basis of lowest effect level 103 . To extend these data from 'associations' to 'cause-and-effect' relationships, we performed an extensive analysis of the literature with a focus on 'interventional' studies in which rodents were exposed to an EDC (or a mixture that might better represent environmental exposures) or vehicle control, and a NAFLD phenotype was scored (see Supplementary information S1 ( Red O staining and hepatic triglyceride measurements). Importantly, both animals exposed to EDCs perinatally (in utero) and those exposed as adults showed signs of steatosis development in response to different doses (see Supplementary information S1 (table) ). Interestingly, the combined treatment of rodents with one type of EDC followed by another class of EDC can modify the NAFLD phenotype. For example, the pre-treatment of rats with TCDD led to the appearance of NAFLD, whereas DEHP pre-treatment ameliorated the TCDD-induced pheno type 104 . Similarly, the combination of TCDD and Aroclor 1254 seemed to worsen NAFLD in mice, compared with treatment with either EDC alone 105 . Although this approach has been applied in only a few experimental settings, the data are extremely relevant to humans, in whom exposure to more than one EDC during development and throughout the course of a lifetime can occur. Additional animal studies examining EDC mixtures are certainly warranted.
When combined with other risk factors for NAFLD (such as a HFD), EDCs generally exacerbate the NAFLD phenotype in exposed rodents. Two seminal studies reported that perinatal exposure to BPA (50-100 μg/kg per day) combined with a HFD after weaning (at postnatal day 21) led to more severe hepatic steatosis in male but not female offspring 106, 107 , and to increased inflammation as well as mild fibrosis in the liver 106 . These data indicate that in addition to increasing hepatic lipid accumulation in the liver, EDC exposure might also trigger macrophage infiltration, which can further contribute to the development of NASH (in an analogous manner to that already proposed for fructose 1 ), although additional mechanistic studies are needed to adequately test this hypothesis. In terms of altered gene expression, the increased hepatic lipid accumulation observed following BPA treatment could be due to an imbalance of FFA uptake, synthesis or β-oxidation, and/or triglyceride export via secretion as VLDL (FIG. 2) . Indeed, the livers of BPA-exposed animals exhibit increased expression of a key gene involved in FFA uptake (namely, Cd36; also known as Fat), and decreased expression of genes involved in triglyceride synthesis and FFA oxidation (namely, Dgat (which encodes diacylglycerol O-acyltransferase 1), Agpat6 (which encodes acyl-CoA:glycerol-3-phosphate acyltransferase 4; also known as GPAT4), Cebpa (which encodes CCAAT/enhancer-binding protein-α), Cebpb (which encodes CCAAT/enhancer-binding protein-β), Pck1 (which encodes cytosolic phosphoenolpyruvate carboxykinase), Acox1, Cpt1a and Cybb (which encodes cytochrome b-245 heavy chain)) 107 . Relevant to the ability of EDCs to induce developmental reprogramming of the epigenome, BPA exposure alters DNA methylation and histone modifications that are associated with active transcription (for example, the acetylation of histones H3 and H4, and the trimethylation of histone H3 at lysine 36), and decreases the occupancy of RNA polymerase II and crucial transcription factors (C/EBPβ and SREBP1) within the Cpt1a gene 107 . Understanding how these epigenetic alterations are modulated by environmental exposures holds promise for understanding the increased NAFLD susceptibility caused by EDC exposure, as well as the gender bias evident from the observation that female rats are refractory to BPA-induced steatosis 106, 107 . Some gender bias might be EDC-specific, given that in other studies both male and female mice and rats exposed to EDCs -such as TBT, polycyclic aromatic hydrocarbons (PAHs) and PCBs -displayed an observable NAFLD-like phenotype (see Supplementary information S1 (table) ).
In addition to BPA, other EDCs can worsen NAFLD when promoted by a HFD (for example, the treatment of mice with PFOA 108 , or the pesticides CYP or ATZ 109 ). Importantly, exposure to some individual EDCs fails to trigger disease, with NAFLD being observed only when EDC exposure is combined with a HFD. For example, the treatment of male mice with PCB153 alone did not lead to NAFLD, whereas NAFLD was observed in HFDfed animals exposed to PCB153 (REF. 110 ). Finally, some EDC exposures might not promote HFD-induced hepatic steatosis but instead induce a NASH-like phenotype. An example of this phenomenon was reported for adult male mice treated with the PCB mixture Aroclor 1260 (REF. 111 ).
Taken together, the existing animal data suggest that EDC exposure might promote NAFLD, and in some cases NASH and fibrosis as well. However, crucial unanswered questions still remain with regard to exactly how exposure to an EDC can promote NAFLD. Whether EDCs affect mainly hepatocytes, or influence the activity and expansion and/or recruitment of hepatic macrophages, sinusoidal endothelial cells or stellate cells, remains to be clarified. Although studies using the aforementioned EDCs certainly support a causal link between EDC exposure and NAFLD (see Supplementary information S1 (table)), they do not inform as to which NRs, co-regulator complexes or epigenetic marks are involved in the increased disease susceptibility. Future studies should assay the appearance or loss of NAFLD in liver-specific NR-deficient mice to identify the NR signalling axis activated by a given EDC exposure. This knowledge could guide the targeting of the correct NR with a selective ligand for therapeutic purposes. In addition, as NAFLD is observed most often in experimental animal studies using a combination of EDC exposure (particularly during early life) and a HFD, defining the interaction between EDC exposure and diets that promote this disease could be important from a prevention standpoint, in addition to efforts to improve dietary habits by encouraging the consumption of a low-fat diet.
In human epidemiological studies, several inherent challenges exist in comparing exposed with non-exposed populations, which makes drawing causal inferences from such studies exceedingly difficult. For example, human exposure to some EDCs -such as short-lived BPAis nearly ubiquitous, with up to 95% of all people in the United States having detectable levels of BPA in their urine 14 . In the case of POPs such as dioxins and PCBs, the EDCs are very long-lived, and this can result in their continual exposure to animals and watersheds that humans consume. The available literature contains cross-sectional epidemiological studies that inherently lack the power of causal prediction. In these studies, several EDCs have been associated with either disrupted liver function (as indicated by measuring the levels of liver enzymes such as aspartate transaminase (AST), alanine transaminase (ALT) or γ-glutamyl transpeptidase) or steatosis (as assayed rarely by biopsy or more frequently by ultrasound): namely, BPA, TCDD, polychlorinated dibenzop-dioxins, dibenzofurans (polychlorinated dibenzodioxins and polychlorinated dibenzofurans), POPs (17 dioxins or furans, and 18 PCB congeners) and PCBs (see Supplementary information S2 (table) ). Importantly, one of these human association studies found that one-third of 55 men exposed to TCDD during a 10-year period had liver biopsy histologies revealing not only steatosis, but also fibrosis or macrophage infiltration 112 . Of note, altered enzymatic markers of liver function more correctly represent 'liver damage' than NAFLD; although elevated serum ALT and AST levels are the primary abnormalities observed in patients with NAFLD, liver enzyme levels can be normal in up to 78% of patients with NAFLD 113 . Overall, the limited epidemiological human data available to date suggest an association, but are insufficient to conclude a cause-effect relationship between EDC exposure and NAFLD in humans.
Mechanisms of EDC action.
A central mechanism by which EDCs are thought to exert long-term adverse health effects is by inducing alterations in the epigenome, which -owing to the heritable nature of epigenetic programmes -can persist across many cell generations and throughout the life course. The term 'epigenetics' was coined to describe a process in which variations in gene expression give rise to distinct patterns of differentiation 114 . A more modern definition of epigenetics describes it as the heritable alterations that regulate gene expression in the absence of changes in DNA sequence. Although every cell in the human body shares essentially the same DNA sequence, epigenetic processes (sometimes referred to as 'programmes') determine the phenotypic heterogeneity that is observed in the different cell types within tissues and organs throughout the body, and during both normal and abnormal physiological function.
DNA methylation was the first-identified molecular mechanism of epigenetic regulation of gene expression 115, 116 , and it occurs via the enzymatic transfer of a methyl group to cytosine bases of DNA, which gives rise to 5-methylcytosine. The addition of methyl groups is the function of DNA methyltransferases (DNMTs), whereas the removal of these methyl groups and the formation of oxidized derivatives of 5-methylcytosine are the functions of ten-eleven translocation (TET) enzymes (FIGS 5, 6) . DNA methylation alters the conformation of DNA via the action of methyl-binding proteins that inhibit the transactivation of gene expression by preventing the binding of transcription factors to promoters [117] [118] [119] and via the recruitment of chromatin-remodelling complexes that 'lock' DNA in a closed chromatin structure 120 . Histone proteins are stably associated with DNA and form the basic scaffolding structure of DNA, which is called the nucleosome 121 . The four core histone proteins (H2A, H2B, H3 and H4) are subjected to post-translational modification of their amino-terminal regions (known as the histone 'tails'), which protrude out from the nucleosome, and provide a platform for the assembly of protein complexes and proteins that 'read' the epigenetics marks present on these tails. The post-translational modification of histones modulates chromatin conformation and gene expression by altering the binding sites for proteins that regulate gene expression or by facilitating the formation of a secondary chromatin structure that controls chromatin accessibility. Combinations of post-translational modifications are both variable and dynamic, generating a 'histone code' or complex language of transcriptional regulation 122, 123 . Like DNA methylation, the methylation Specific arginine and lysine residues on histone tails are methylated by distinct histone methyltransferases (HMTs), whereas DNA methylation is mediated by DNA methyltransferases (DNMTs). Both HMTs and DNMTs use S-adenosyl-l-methionine (SAM) as their methyl (Me) donor. SAM is created from methionine, and its levels are influenced by the interconnected methionine and folate cycles. Importantly, high-folate maternal diets in rodents have been shown to affect the DNA methylation patterns of their offspring [163] [164] [165] . F-THF, 10-formyl-tetrahydrofolate; Me-THF, 5,10-methylene-THF; MTHF, 5-methyl-THF; SAH, S-adenosyl-l-homocysteine. of histones is a stable epigenetic modification, and patterns of histone methylation can be epigenetically inherited across cell divisions and the life course. Histone methylation is regulated by the action of histone methyltransferases (HMTs) and histone demethylases (HDMs) that add or remove methyl groups, respectively (FIG. 6) . Histone methylation is associated with both transcriptional activation and repression depending on the specific residue that is modified. Histones can also be acetylated (a modification that is transient relative to methylation) by histone acetyltransferase (HAT) enzymes; acetylation is associated with an open chromatin conformation and the activation of gene expression 124 . Conversely, the deacetylation of histones by histone deacetylases (HDACs) promotes the condensation of chromatin and the repression of transcription 125, 126 . The methyl groups used for both DNA and histone methylation are derived from one-carbon metabolism and utilize the same methyl donor, S-adenosyl-lmethionine (SAM). Both DNMTs and HMTs transfer methyl groups from SAM to cytosine in DNA and to lysine or arginine residues on histone tails, respectively, forming the by-product S-adenosyl-l-homocysteine (SAH) (FIG. 5) . The liver has a major role in SAM metabolism, and SAM biosynthesis and degradation is regulated by the enzymes methionine adenosyltransferase and glycine-N-methyltransferase (GNMT), respectively 127 . The maintenance of SAM homeostasis is necessary for liver health, and for preventing injury and HCC 4, 128 . For example, knockout of Mat1a (which encodes SAM synthase isoform type 1) in mice results in chronic SAM deficiency and increased susceptibility to steatosis in response to a choline-deficient diet, and leads to the spontaneous development of NASH 129 . Gnmt-knockout mice (which display chronic SAM excess) also develop liver steatosis, fibrosis and HCC, and simultaneously show increased DNA and histone methylation 130 . Interestingly, the observed liver phenotype and DNA hypermethylation in Gnmt-knockout mice can be reversed upon treatment with nicotinamide, which markedly reduces SAM levels 131 . Furthermore, children with mutations in GNMT exhibit mild-to-moderate liver disease 132, 133 . Collectively, these data support a role for the disruption of SAM homeostasis in the development of liver disease.
In adult rodents, exposure to a methyl-deficient diet (MDD) results in increased hepatic steatosis and the alteration of DNA methylation [134] [135] [136] [137] . For example, MDD exposure causes the hypermethylation of Ahcy, which encodes the enzyme that is responsible for hydrolysis of SAH, and thus increases SAH levels 137 . Interestingly, individual mouse strains exhibit differential susceptibility to MDD-induced liver disease, and this difference might be due to inter-strain epigenetic differences. For example, the WSB/EiJ strain exhibits severe NASH-like liver injury in response to a MDD, whereas the A/J strain exhibits mild NAFLD-like liver injury in response to a MDD 135, 136 ; increased DNA methylation at gene promoters and increased Dnmt1 and Dnmt3a expression 136 have been reported in the more susceptible WSB/EiJ strain, and this is consistent with the hypothesis that epigenetic alterations might have a role in modulating NAFLD susceptibility.
Few studies to date have examined the role of histone modifications in NAFLD, but evidence indicates that an imbalance between HATs and HDACs might have a role in the progression of NAFLD 138 . For example, liverspecific knockout of the gene encoding the HDAC sirtuin 1 (SIRT1) increases susceptibility to HFD-induced hepatic steatosis 139 . In addition, HDAC3 has been shown to control hepatic lipogenesis in a circadian fashion, and the deletion of Hdac3 causes hepatic steatosis 140 . Furthermore, adult mice fed a HFD exhibit altered histone acetylation at genes involved in the inflammatory response 141 . Studies in primates have examined the epi genetic effects of maternal diet on liver disease in offspring. A maternal HFD alters histone acetylation in the livers of offspring, with a concomitant increase in the expression of genes involved in lipogenesis, and a decrease in HDAC1 and SIRT1 expression and activity 142, 143 . Interestingly, these effects can be abrogated by diet reversal 143 . A similar lack of data exists for alterations in DNA methylation that are associated with NAFLD, although nutrient modulation of DNA methylation in the context of obesity has been demonstrated in the Agouti mouse model 144, 145 . Constitutive, ectopic Agouti transcription (due to altered DNA methylation) results in a yellow-coat phenotype, as well as increased susceptibility to diabetes mellitus, obesity and tumorigenesis 146, 147 . Maternal nutrient supplementation with the phyto-oestrogen (and EDC) genistein alters coat colour and protects offspring from obesity by modifying the fetal epigenome 148 . Supplementation with genistein (or folic acid) also counteracts BPA-mediated DNA hypo methyl ation in early development in this mouse model 149 . These studies support the use of the Agouti mouse as a biosensor Figure 6 | Early-life exposure to endocrine-disrupting chemicals triggers the development of nonalcoholic fatty liver disease. Exposure to endocrine-disrupting chemicals (EDCs) during the prenatal period (a critical 'window of susceptibility') can result in changes to the liver epigenome that influence an individual's susceptibility to liver disease in adulthood. The activity of epigenetic 'writers' of DNA (DNA methyltransferases (DNMTs)) or histone (histone methyltransferases (HMTs) methyl marks (Me), and 'erasers' of these heritable marks (ten-eleven translocation (TET) or histone demethylases (HDMs), respectively) can be influenced by a prenatal EDC exposure, which changes their activity and alters the epigenome. Such epigenetic reprogramming could confer individuals with a propensity to develop nonalcoholic fatty liver disease (NAFLD) in adulthood via the reprogrammed expression of genes involved in lipid homeostasis. for the study of epigenomic modulation by the environment 144 , including future studies that aim to examine the link between DNA methylation and the development of NAFLD. In humans, only a few of studies have reported gene-specific alterations in DNA methylation in patients with advanced NAFLD compared with those who have mild NAFLD 150, 151 , which highlights the need for additional research in this area.
Liver disease and environmental exposures across the life course. Although adverse environmental exposures can act at any time throughout the life course to increase the risk of disease, the perinatal period might represent a window of particular vulnerability 152 . For example, in the context of rodent models of nutritional modulation, a maternal energy-rich diet is associated with the development of NAFLD in offspring [153] [154] [155] [156] [157] [158] [159] [160] [161] . In addition, as mentioned above, studies in humans have shown that fetal exposure to famine that is 'mismatched' with a nutrient-rich adult environment 19, 162 is associated with the development of hepatic steatosis. Similarly, perinatal exposure to EDCs can result in adult susceptibility to the development of NAFLD in rodent models (see Supplementary information S1 (table)), although only a limited number of these studies have examined epigenetic alterations that could be responsible for NAFLD susceptibility. To date, most studies have focused on epigenetic alterations that are associated with the disease itself, rather than with a change in the susceptibility of the liver that precedes disease onset. Therefore, it remains an attractive but untested hypothesis that early-life exposure to EDCs might increase the risk of liver disease by altering patterns of DNA and/or histone methylation, and thereby changing physiological set points in the liver to reprogramme hepatic gene expression programmes and thus promote NAFLD (FIG. 6 ).
An intriguing but underexplored aspect of the EDC-NAFLD link is the interplay among EDC exposure, obesity and NAFLD. As obesity is a known risk factor for NAFLD, early-life exposure to EDCs that act as obesogens could increase an individual's susceptibility to NAFLD by increasing their susceptibility to obesity. Early-life EDC exposure could also deliver a 'double hit' by altering both liver physiological set points and causing other physiological changes that increase the propensity for obesity. Alternatively, susceptibility to the NAFLDpromoting effects of later-life EDC exposure could be increased in obese individuals. Just as obesity combined with alcohol increases the risk of fatty liver disease, so could the physiological effects of other risk factorssuch as obesity, a HFD and T2DM -combine with EDC exposure. The impact of early-life EDC exposure Figure 7 | Exposure to endocrine-disrupting chemicals and the risk of nonalcoholic fatty liver disease across the life course. Endocrine-disrupting chemicals (EDCs) can alter an individual's susceptibility to the development of nonalcoholic fatty liver disease (NAFLD) via early-life effects that increase susceptibility to obesity and alter hepatic 'set points' to favour the development of steatosis and via later-life effects that contribute to the development of liver disease alone or in combination with other NAFLD risk factors such as diet, diabetes mellitus and/or obesity. HFD, high-fat diet; NASH, nonalcoholic steatohepatitis.
and later-life EDC exposure in the setting of other risk factors such as obesity are therefore important areas for future investigation in studies that aim to improve our understanding of the potential contribution of EDCs to the development and progression of NAFLD (FIG. 7) .
Conclusions NAFLD -which has the most rapidly rising prevalence and is the most prevalent liver disease worldwide -represents diseases that range from simple steatosis to steatohepatitis, and can progress to fatal cirrhosis and HCC. In addition to obesity and fructose acting as risk factors for NAFLD development and progression, environmental exposure to certain chemicals such as EDCs might increase an individual's susceptibility to NAFLD and/or cooperate with a Western HFD to promote the development of this disease. One mechanism of EDC action involves physical binding to NRs, which then can recruit co-regulator proteins (either co-activators or co-repressors) to modulate the transcription of gene expression programmes that are involved in hepatic lipid homeostasis to favour NAFLD. In addition, early-life EDC exposure can affect the epigenome by altering DNA methylation and/or histone modifications, thus affecting metabolic reprogramming via the altered expression of genes involved in hepatic lipid pathways. Such reprogramming of the epigenome during development in response to nutrient availability is well established; EDC exposure in early life might similarly reprogramme gene programmes that are involved in hepatic lipid homeostasis towards a metabolic set point that promotes NAFLD. In addition, EDC exposure in adulthood might also contribute to the development of NAFLD in combination with other prevalent predisposing factors, such as diets rich in fat, a BMI >30 kg/m 2 and T2DM. We hope that this Review will encourage more mechanistic studies that aim to better understand how EDC exposures affect the epigenome, thus altering the expression of genes associated with hepatic lipid metabolism, which in turn promote the development of NAFLD.
